Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease
Where Has the Pendulum Swung?
DOI:
https://doi.org/10.58931/cibdt.2023.117Keywords:
therapeutic drug monitoring, biologics, inflammatory bowel diseaseAbstract
Biologics have revolutionized the management of patients with inflammatory bowel disease (IBD), in both ulcerative colitis (UC) and Crohn’s disease (CD). There are several classes of biologics used to treat IBD, including monoclonal antibodies directed against TNF, integrin, IL12/23, and IL-23 monoclonal antibodies. Despite the effectiveness of anti-TNF medications, approximately 30% of patients are primary non-responders (PNR), and another 50% lose response over time (secondary loss of response [SLR]). Therapeutic drug monitoring (TDM) provides a tool for biologic dose optimization by measuring drug trough concentrations and anti-drug antibodies (ADA). Drug concentrations are positively correlated to therapeutic benefits, but questions remain on how, when and for whom to perform TDM. Successful implementation is challenged by several factors such as variations in optimal drug targets, different types of drug detection assays, individual pharmacokinetics, and disease severity. Over recent years, various expert groups have provided guidelines on reactive TDM of anti-TNF therapies; however, a knowledge gap still exists on the role of proactive TDM, as well as reactive TDM for non-anti-TNF biologics. The most recent and comprehensive expert consensus statement published in the American Journal of Gastroenterology (AJG), attempted to fill this gap by advocating for the use of reactive TDM for anti-TNF medications, as well as for proactive TDM in certain scenarios.
References
Cheifetz AS, Abreu MT, Afif W, Cross RK, Dubinsky MC, Loftus EV, Osterman MT, Saroufim A, Siegel CA, Yarur AJ, Melmed GY. A comprehensive literature review and expert consensus statement on therapeutic drug monitoring of biologics in inflammatory bowel disease. Am J Gastroenterol. 2021 Oct 13;116(10):2014-25. DOI: https://doi.org/10.14309/ajg.0000000000001396
Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, Thomas A, Nice R, Perry MH, Bouri S, Chanchlani N. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn’s disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019 May 1;4(5):341-53.
Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S, Gerson L, Hirano I, Rubenstein JH, Smalley WE, Stollman N, Sultan S. American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology. 2017 Sep 1;153(3):827-34. DOI: https://doi.org/10.1053/j.gastro.2017.07.032
Lefevre PL, Shackelton LM, Vande Casteele N. Factors influencing drug disposition of monoclonal antibodies in inflammatory bowel disease: implications for personalized medicine. BioDrugs. 2019 Oct;33(5):453-68. DOI: https://doi.org/10.1007/s40259-019-00366-1
Sazonovs A, Kennedy NA, Moutsianas L, Heap GA, Rice DL, Reppell M, Bewshea CM, Chanchlani N, Walker GJ, Perry MH, McDonald TJ. HLA-DQA1* 05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn’s disease. Gastroenterology. 2020 Jan 1;158(1):189-99.
Casteele NV, Herfarth H, Katz J, Falck-Ytter Y, Singh S. American Gastroenterological Association Institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases. Gastroenterology. 2017 Sep 1;153(3):835-57. DOI: https://doi.org/10.1053/j.gastro.2017.07.031
Yanai H, Lichtenstein L, Assa A, Mazor Y, Weiss B, Levine A, Ron Y, Kopylov U, Bujanover Y, Rosenbach Y, Ungar B. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin Gastroenterol Hepatol. 2015 Mar 1;13(3):522-30. DOI: https://doi.org/10.1016/j.cgh.2014.07.029
Kelly OB, Donnell SO, Stempak JM, Steinhart AH, Silverberg MS. Therapeutic drug monitoring to guide infliximab dose adjustment is associated with better endoscopic outcomes than clinical decision making alone in active inflammatory bowel disease. Inflamm Bowel Dis. 2017 Jul 1;23(7):1202-9. DOI: https://doi.org/10.1097/MIB.0000000000001126
Singh S, George J, Boland BS, Vande Casteele N, Sandborn WJ. Primary non-response to tumor necrosis factor antagonists is associated with inferior response to second-line biologics in patients with inflammatory bowel diseases: a systematic review and meta-analysis. J Crohns Colitis. 2018 May 25;12(6):635-43. DOI: https://doi.org/10.1093/ecco-jcc/jjy004
Mack DR, Benchimol EI, Critch J, deBruyn J, Tse F, Moayyedi P, Church P, Deslandres C, El-Matary W, Huynh H, Jantchou P. Canadian association of gastroenterology clinical practice guideline for the medical management of pediatric luminal Crohn’s disease. Gastroenterology. 2019 Aug 1;157(2):320-48. DOI: https://doi.org/10.1053/j.gastro.2019.03.022
Al-Bawardy B, Ramos GP, Willrich MA, Jenkins SM, Park SH, Aniwan S, Schoenoff SA, Bruining DH, Papadakis KA, Raffals L, Tremaine WJ. Vedolizumab drug level correlation with clinical remission, biomarker normalization, and mucosal healing in inflammatory bowel disease. Inflamm Bowel Dis. 2019 Feb 21;25(3):580-6. DOI: https://doi.org/10.1093/ibd/izy272
Battat R, Kopylov U, Bessissow T, Bitton A, Cohen A, Jain A, Martel M, Seidman E, Afif W. Association between ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2017 Sep 1;15(9):1427-34. DOI: https://doi.org/10.1016/j.cgh.2017.03.032
Assa A, Matar M, Turner D, Broide E, Weiss B, Ledder O, Guz-Mark A, Rinawi F, Cohen S, Topf-Olivestone C, Shaoul R. Proactive monitoring of adalimumab trough concentration associated with increased clinical remission in children with Crohn’s disease compared with reactive monitoring. Gastroenterology. 2019 Oct 1;157(4):985-96. DOI: https://doi.org/10.1053/j.gastro.2019.06.003
Nguyen N, Solitano V, Vuyyuru S et al. Proactive therapeutic drug monitoring versus conventional management for inflammatory bowel diseases: a systemic review and meta-analysis. Gastroenterology. 2022;163(4):937-949.e2. DOI: https://doi.org/10.1053/j.gastro.2022.06.052
Casteele NV, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K, Simoens S, Rutgeerts P, Gils A, Vermeire S. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015 Jun 1;148(7):1320-9. DOI: https://doi.org/10.1053/j.gastro.2015.02.031
D’Haens GR, Vermeire S, Lambrecht G, Baert F, Bossuyt P, Nachury M, Buisson A, Bouhnik Y, Filippi J, Vande Woude J, Van Hootegem P. Drug-concentration versus symptom-driven dose adaptation of infliximab in patients with active Crohn’s disease: a prospective, randomised, multicentre trial (Tailorix). J Crohns Colitis. 2016;10:S24. DOI: https://doi.org/10.1093/ecco-jcc/jjw019.028
Strik AS, Löwenberg M, Mould DR, Berends SE, Ponsioen CI, van den Brande JM, Jansen JM, Hoekman DR, Brandse JF, Duijvestein M, Gecse KB. Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial. Scand J Gastroenterol. 2021 Feb 1;56(2):145-54. DOI: https://doi.org/10.1080/00365521.2020.1856405
Syversen SW, Goll GL, Jørgensen KK, Olsen IC, Sandanger Ø, Gehin JE, Warren DJ, Sexton J, Mørk C, Jahnsen J, Kvien TK. Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study). Trials. 2020 Dec;21(1):1-4. DOI: https://doi.org/10.1186/s13063-019-3734-4
D’Haens G, Vermeire S, Lambrecht G, Baert F, Bossuyt P, Pariente B, Buisson A, Bouhnik Y, Filippi J, Vander Woude J, Van Hootegem P. Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, and corticosteroid-free remission in patients with active luminal Crohn’s disease. Gastroenterology. 2018 Apr 1;154(5):1343- 51. DOI: https://doi.org/10.1053/j.gastro.2018.01.004
Lucidarme C, Petitcollin A, Brochard C, Siproudhis L, Dewitte M, Landemaine A, Bellissant E, Bouguen G. Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring. Aliment Pharmacol Ther. 2019 Jan;49(2):147-54. DOI: https://doi.org/10.1111/apt.15046
Van Assche G, Magdelaine–Beuzelin C, d’Haens G, Baert F, Noman M, Vermeire S, Ternant D, Watier H, Paintaud G, Rutgeerts P. Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology. 2008 Jun 1;134(7):1861-8. DOI: https://doi.org/10.1053/j.gastro.2008.03.004
Colombel JF, Adedokun OJ, Gasink C, Gao LL, Cornillie FJ, D’Haens GR, Rutgeerts PJ, Reinisch W, Sandborn WJ, Hanauer SB. Combination therapy with infliximab and azathioprine improves infliximab pharmacokinetic features and efficacy: a post hoc analysis. Clin Gastroenterol Hepatol. 2019 Jul 1;17(8):1525-32. DOI: https://doi.org/10.1016/j.cgh.2018.09.033
Shukla R, Ananthakrishnan A. Therapeutic drug monitoring of non-anti-tumor necrosis factor biologics. Clin Gastroenterol Hepatol. 2021 Jun 1;19(6):1108-10. DOI: https://doi.org/10.1016/j.cgh.2021.01.002
Irving PM, Gecse KB. Optimizing therapies using therapeutic drug monitoring: current strategies and future perspectives. Gastroenterology. 2022 Apr;162(5):1512-24. doi:10.1053/j.gastro.2022.02.014 DOI: https://doi.org/10.1053/j.gastro.2022.02.014
Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee BH, Lomer MC, Parkes GC, Selinger C, Barrett KJ. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019 Dec 1;68(Suppl 3):s1-06. DOI: https://doi.org/10.1136/gutjnl-2019-318484
Adamina M, Bonovas S, Raine T, Spinelli A, Warusavitarne J, Armuzzi A, Bachmann O, Bager P, Biancone L, Bokemeyer B, Bossuyt P. ECCO guidelines on therapeutics in Crohn’s disease: surgical treatment. J Crohns Colitis. 2020 Feb 10;14(2):155-68. DOI: https://doi.org/10.1093/ecco-jcc/jjz187
Mitrev N, Vande Casteele N, Seow CH, Andrews JM, Connor SJ, Moore GT, Barclay M, Begun J, Bryant R, Chan W, Corte C. consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017 Dec;46(11-12):1037-53. DOI: https://doi.org/10.1111/apt.14368
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Canadian IBD Today
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
